<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318655</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00020</org_study_id>
    <nct_id>NCT01318655</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects</brief_title>
  <acronym>Japan SMAD</acronym>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of NKTR-118 Following Single and Multiple Ascending Oral Dose Administration in Healthy Young and Elderly Japanese Subjects, and an Open Randomized, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics After Single Oral Doses of NKTR-118 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of NKTR-118 with healthy
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety,
      Tolerability and Pharmacokinetics of NKTR-118 following single and multiple ascending oral
      dose administration in healthy young and elderly Japanese subjects, and an Open Randomized,
      Crossover Study to Investigate the Effect of Food on the Pharmacokinetics after single oral
      doses of NKTR-118 in healthy male Japanese subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate the safety and tolerability of NKTR-118 using incidence of Adverse Events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of drug concentrations in plasma by characterizing PK parameters (AUC)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of drug concentrations in plasma by characterizing PK parameters (Cmax)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NKTR-118</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-118</intervention_name>
    <description>Tablet, Oral, Once daily</description>
    <arm_group_label>NKTR-118</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, Oral, Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 Years to 45 Years, 65 Years to 80 Years

          -  Body mass index (BMI): 18 to 27 kg/m

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the day
             of dosing until 3 months after dosing with the investigational product.

          -  Non-smokers or ex-smokers (not smoked in the past 3 months).

        Exclusion Criteria:

          -  Clinically relevant disease and/or abnormalities (past or present)

          -  Clinically relevant abnormalities in physical examinations,vital signs,clinical
             chemistry, hematology or urinalysis as judged by the investigator

          -  Use of any prescribed or non-prescribed medication including herbal remedies, vitamins
             and minerals during the two weeks prior to the first administration of investigational
             product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shunji Matsuki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyusyu Clinical Phramacology Research Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yukiya Sasaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>&quot;Chuo-ku&quot;</city>
        <state>&quot;Fukuoka&quot;</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Japan</keyword>
  <keyword>SAD</keyword>
  <keyword>MAD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

